

LACK  
OF SLEEP  
DIZZINESS  
DOUBLE  
VISION  
LOSS OF BALANCE  
MIGRAINE  
SLURRED SPEECH  
NAUSEATING  
RINGING  
OF EARS  
CONSTIPATION  
WEAKNESS  
SENSITIVITY TO  
LIGHT SOUND

**Adult  
Acute Migraine  
Pain Protocol**

#ListenToPain

## ADULT ACUTE MIGRAINE PAIN PROTOCOL

### STEP 1: ASSESS MIGRAINE HEADACHE

#### ASK THE PATIENT ABOUT MIGRAINE HEADACHE SYMPTOMS<sup>1,2</sup>

Pulsatile quality of headache	Duration of headache (4 to 72 hours if untreated)	Unilateral headache	Nausea or vomiting	Disabling intensity of headache
-------------------------------	---	---------------------	--------------------	---------------------------------

#### IDENTIFY SYMPTOMS OR CIRCUMSTANCES REQUIRING REFERRAL<sup>1,2</sup>

- Change in established headache pattern or "the worst headache ever"
- New onset after 50 years of age
- Progressively increasing severity
- Symptoms of systemic disorders (e.g., fever, hypertension, myalgia, weight loss)

- "Thunderclap" headache (maximum severity at onset)
- Neurologic signs or seizures
- Neck stiffness
- Headache aggravated by postures

### STEP 2: IDENTIFY TREATMENT CONSIDERATIONS

#### IDENTIFY ANY CONDITIONS OR MEDICATIONS LIMITING TREATMENT OPTIONS

##### Medications limiting treatment<sup>2-5</sup>

- NSAIDs\* – risk of bleeding, decreased antihypertensive efficacy, increased drug levels of medicines like methotrexate
- Paracetamol: Increased risk of paracetamol toxicity
- Triptans - Contraindicated in cardiovascular or cerebrovascular disease, uncontrolled hypertension and specific migraine syndromes.

##### Medical conditions limiting treatment<sup>3,6-9</sup>

- Chronic kidney disease
- Liver disease
- Peptic ulcer disease
- Cardiovascular disease
- Cerebrovascular Disease

NSAIDs, non-steroidal anti-inflammatory drugs; \* With oral NSAIDs only

#### IDENTIFY WHAT THE PATIENT HAS USED IN THE PAST TO TREAT MIGRAINE HEADACHE

### STEP 3: RECOMMEND TREATMENT

#### DOES THE PATIENT HAVE ANY PREFERENCE FOR TREATMENT BASED ON WHAT WAS USED IN THE PAST?

##### IF YES

- Recommend non-pharmacological treatment<sup>10</sup>
- Using a diary for identifying important migraine triggers
  - Good sleep hygiene practices
  - Dietary lifestyle modifications
  - Regular and moderate exercise
  - Stress management
  - Weight reduction to restore an ideal body weight
  - Patient education

##### IF NO

- Recommend non-pharmacological treatment<sup>10</sup>
- Using a diary for identifying important migraine triggers
  - Good sleep hygiene practices
  - Dietary lifestyle modifications
  - Regular and moderate exercise
  - Stress management
  - Weight reduction to restore an ideal body weight
  - Patient education

# ADULT MIGRAINE PROTOCOL

## STEP 3: RECOMMEND TREATMENT (CONT.)

### AND

Recommend the PATIENT's preference if possible, taking into consideration step 2

### AND

Recommend appropriate acute migraine treatment<sup>1,2</sup>

- **First-line medications:**
  - Aspirin 900–1000 mg
  - Ibuprofen 400 - 600 mg
  - Diclofenac 50 mg oral (soluble)
  - Paracetamol 1000 mg (for patients intolerant to NSAIDs)
- **Second-line medications:**
  - Triptans (Sumatriptan, Zolmitriptan)
- **Third-line medications:**
  - Ditans (Lasmiditan) or gepants (Ubrogepant)
- **Combination therapy:**
  - Paracetamol + aspirin + caffeine (in patients with contraindications to vasoconstrictors like Triptans))
- **Adjunct medications for patients who experience nausea and/or vomiting during migraine attacks:**
  - Domperidone (10 mg) and metoclopramide (10 mg)

# ADULT HEADACHE ALGORITHM

## STEP 1

### ASSESS SYMPTOMS

- Questions to ask (Table 1)
- Assess Migraine Type (Table 2)
- Symptoms or circumstances requiring referral (Table 3)

## → STEP 2

### IDENTIFY TREATMENT CONSIDERATIONS

- Questions to ask to customize migraine treatment (Table 4)
- Conditions and medications (Tables 5 and 6)
- Assess previous treatment (Table 7)
- Questions to ask about previous treatment (Table 7)

## → STEP 3

### RECOMMEND TREATMENT

- Non-pharmacological recommendations (Table 8)
- Pharmacological recommendation (Table 9)

## STEP 1: ASSESS SYMPTOMS

**TABLE 1**

QUESTIONS TO ASK
<p><b>Can you tell me about your headache symptoms?<sup>2</sup></b></p> <ul style="list-style-type: none"> <li>• Do you have recurrent headache of moderate to severe intensity?</li> <li>• Is the pain unilateral and/or pulsating?</li> <li>• What is the duration of the headache episode? (Is it 4 to 72 hours if untreated or unsuccessfully treated)</li> <li>• Do you have a disabling intensity of headache?</li> <li>• Was the onset of symptoms at or around puberty?</li> </ul>
<p><b>Do you have any other symptoms?<sup>2</sup></b></p> <ul style="list-style-type: none"> <li>• Do you have sensitivity to light and/or sound?</li> <li>• Is the headache accompanied with nausea and/or vomiting?</li> <li>• Do you have visual disturbances with the headache?</li> <li>• Look for symptoms that require referral to a doctor (red flag symptoms)</li> </ul>
<p><b>Do you have a family history of migraine?<sup>2</sup></b></p>

**→ TABLE 2**

ICHD-3* DIAGNOSTIC CRITERIA FOR DIFFERENT TYPES OF MIGRAINE HEADACHES <sup>2,13</sup>	
Migraine without aura	Migraine with aura
<ol style="list-style-type: none"> <li>1. At least five attacks that fulfil criteria 2–5</li> <li>2. Headache attacks that last 4–72 h when untreated or unsuccessfully treated</li> <li>3. Headache has at least two of the following four characteristics: <ul style="list-style-type: none"> <li>• unilateral location</li> <li>• pulsating quality</li> <li>• moderate or severe pain intensity</li> <li>• aggravation by, or causing avoidance of, routine physical activity (for example, walking or climbing stairs)</li> </ul> </li> <li>4. At least one of the following during the headache: <ul style="list-style-type: none"> <li>• nausea and/or vomiting</li> <li>• photophobia and phonophobia</li> </ul> </li> <li>5. Not better accounted for by another ICHD-3 diagnosis</li> </ol>	<ol style="list-style-type: none"> <li>1. At least two attacks that fulfil criteria 2 &amp; 3</li> <li>2. One or more of the following fully reversible aura symptoms: <ul style="list-style-type: none"> <li>• visual</li> <li>• sensory</li> <li>• speech and/or language</li> <li>• motor</li> <li>• brainstem</li> <li>• retinal</li> </ul> </li> <li>3. At least three of the following six characteristics: <ul style="list-style-type: none"> <li>• at least one aura symptom spreads gradually over ≥5 min</li> <li>• two or more aura symptoms occur in succession</li> <li>• each individual aura symptom lasts 5–60 min</li> <li>• at least one aura symptom is unilateral</li> <li>• at least one aura symptom is positive</li> <li>• the aura is accompanied with or followed by headache within 60 min</li> </ul> </li> <li>4. Not better accounted for by another ICHD-3 diagnosis</li> </ol>

## STEP 1: ASSESS SYMPTOMS

### → TABLE 2 CONT.

Chronic Migraine
<ol style="list-style-type: none"> <li>1. Headache (migraine- like or tension- type- like) on <math>\geq 15</math> days/month for <math>&gt;3</math> months that fulfil criteria 2 and 3</li> <li>2. Attacks occur in an individual who has had at least five attacks that fulfil the criteria for migraine without aura and/or for migraine with aura</li> <li>3. On <math>\geq 8</math> days/month for <math>&gt;3</math> months, any of the following criteria are met: <ul style="list-style-type: none"> <li>• criteria 3 and 4 for migraine without aura</li> <li>• criteria 2 and 3 for migraine with aura</li> <li>• believed by the patient to be migraine at onset and relieved by a triptan or ergot derivative</li> </ul> </li> <li>4. Not better accounted for by another ICHD-3 diagnosis</li> </ol>
Medication overuse headache (MOH)
<ol style="list-style-type: none"> <li>1. Headache on <math>\geq 15</math> days/month in an individual with a pre- existing headache disorder</li> <li>2. Regular overuse for <math>&gt;3</math> months of one or more drugs that can be taken for acute and/or symptomatic treatment of headache (regular intake of one or more non- opioid analgesics on <math>\geq 15</math> days/month for <math>\geq 3</math> months or any other acute medication or combination of medications on <math>\geq 10</math> days/month for <math>\geq 3</math> months)</li> <li>3. Not better accounted for by another ICHD-3 diagnosis-</li> </ol>
<i>*ICHD: International Classification of Headache Disorders</i>

### → TABLE 3

SYMPTOMS OR CIRCUMSTANCES REQUIRING REFERRAL <sup>2</sup>	
When to look	Physical examination
<b>Patient history</b>	<ul style="list-style-type: none"> <li>• Thunderclap headache</li> <li>• Atypical aura</li> <li>• Head trauma</li> <li>• Progressive headache</li> <li>• Headache aggravated by postures or manoeuvres that raise intracranial pressure</li> <li>• Headache brought on by sneezing, coughing or exercise</li> <li>• Headache associated with weight loss and/or change in memory or personality</li> <li>• Headache onset at <math>&gt;50</math> years of age</li> </ul>
<b>Physical examination</b>	<ul style="list-style-type: none"> <li>• Unexplained fever</li> <li>• Neck stiffness</li> <li>• Focal neurological symptoms</li> <li>• Weight loss</li> <li>• Impaired memory and/or altered consciousness or personality</li> </ul>

## STEP 2: IDENTIFY TREATMENT CONSIDERATIONS

**TABLE 4**

QUESTIONS TO ASK TO CUSTOMIZE HEADACHE TREATMENT
<ul style="list-style-type: none"> <li>• Are you taking any medication, both prescribed and over the counter? If yes, what are those and what is the dose?</li> <li>• Do you have any medical conditions?</li> <li>• What have you used before for your headache?</li> <li>• What are the triggers for your headache?</li> <li>• What are the aggravating or relieving factors?</li> <li>• Is there a family history of migraine?</li> </ul>

**→ TABLE 5**

MEDICATIONS TO USE WITH CAUTION WITH PARACETAMOL/ORAL NSAIDS AND TRIPTANS <sup>3-5,14</sup>	
Concern	Potential drug interaction
Increased risk of bleeding with oral NSAIDs	<ul style="list-style-type: none"> <li>• Some Selective-Serotonin Reuptake Inhibitors (SSRI)</li> <li>• Some tricyclic antidepressants</li> <li>• Acetylsalicylic acid (ASA)</li> <li>• Corticosteroids</li> <li>• Warfarin</li> <li>• Ginkgo biloba</li> </ul>
Decreased antihypertensive efficacy with oral NSAIDs	<ul style="list-style-type: none"> <li>• Angiotensin converting enzyme (ACE) inhibitors</li> <li>• Angiotensin II receptor blockers (ARB)</li> <li>• Diuretics</li> <li>• Beta-blockers</li> </ul>
Increased drug levels with oral NSAIDs	<ul style="list-style-type: none"> <li>• Lithium</li> <li>• Methotrexate</li> </ul>
Increased risk of paracetamol toxicity	<ul style="list-style-type: none"> <li>• Epilepsy medications (e.g. carbamazepine)</li> <li>• Other P450 enzyme inducers (e.g. isoniazid, rifampin)</li> <li>• Alcohol</li> </ul>
Excessive blood vessel narrowing	<ul style="list-style-type: none"> <li>• Triptans and Ergot Alkaloids</li> </ul>
Excessive levels of serotonin	<ul style="list-style-type: none"> <li>• Triptans and a serotonin reuptake inhibitor antidepressant (SSRI) or serotonin norepinephrine reuptake inhibitor (SNRI)</li> </ul>

## STEP 2: IDENTIFY TREATMENT CONSIDERATIONS

→ TABLE 6

CONSIDERATIONS WHEN SELECTING ANALGESICS IN PATIENTS WITH COMORBIDITIES <sup>5-9</sup>	
Comorbidity	Notes
Chronic kidney disease <sup>6</sup>	<ul style="list-style-type: none"> <li>NSAIDs have proven nephrotoxic class effects and should be avoided where possible in patients with symptoms of renal impairment</li> <li>Paracetamol is the preferred first-line analgesic for episodic treatment of mild pain in patients with renal dysfunction, CKD, and/or requiring dialysis. However, dose minimization may sometimes be warranted (maximum of 3 g/day has been recommended for patients with advanced kidney failure)</li> </ul>
Liver disease <sup>6,7</sup>	<ul style="list-style-type: none"> <li>NSAIDs- NSAIDs can cause acute liver injury with variable severity.</li> <li>Paracetamol: Not contraindicated in liver disease. Can cause liver toxicity if taken in large amounts.</li> </ul>
Peptic-ulcer disease <sup>6,8</sup>	<ul style="list-style-type: none"> <li>Chronic NSAID drug use is associated with potentially serious upper gastrointestinal adverse drug reactions including peptic ulcer disease and gastrointestinal bleeding.</li> <li>Paracetamol – Lesser risk of adverse effects compared to NSAIDs</li> </ul>
Cardiovascular disease <sup>3,6,8</sup>	<ul style="list-style-type: none"> <li>All non-aspirin NSAIDs may be associated with a potential increase in CV thrombotic risk.</li> <li>NSAIDs are contraindicated in patients who have undergone coronary artery bypass graft surgery</li> <li>Use of paracetamol at recommended doses is not associated with any additional risk of major CV events.</li> </ul>

→ TABLE 7

QUESTIONS TO ASK TO ABOUT PREVIOUS TREATMENT
<ul style="list-style-type: none"> <li>What have you used before to treat your migraine headache?               <ul style="list-style-type: none"> <li>What dose did you use?</li> <li>Was it effective?</li> <li>Did you have any side effects from it?</li> </ul> </li> <li>Do you have any preference for any specific treatment?</li> </ul>



## STEP 3: RECOMMEND TREATMENT

**TABLE 8**

<b>NON-PHARMACOLOGICAL RECOMMENDATIONS FOR MIGRAINE HEADACHE<sup>2</sup></b>
<p><b>Using a diary for identifying important triggers, avoid the trigger factors if possible or cope with them</b></p> <ul style="list-style-type: none"> <li>• Environmental triggers: Weather and its changes, including decreased atmospheric pressure, low temperature, and high humidity.</li> <li>• Sensitivity to odors (perfumes, cigarette smoke, and cleaning products)</li> <li>• Noise triggers (neighborhood noise from roads, railways etc.)</li> </ul>
<p><b>Good sleep hygiene practices</b></p> <ul style="list-style-type: none"> <li>• Convenient bedrooms with fewer stimulations such as television, cell phone, light, and noise</li> <li>• Waking at a specific time range in the mornings, even on weekends</li> </ul>
<p><b>Dietary lifestyle modifications</b></p> <ul style="list-style-type: none"> <li>• Preventing hunger and fasting, having regular meals</li> <li>• Sticking to frequent meals (e.g. five or six small meals per day)</li> <li>• Consuming foods that provide a stable level of blood glucose (slow-digesting foods)</li> <li>• Cooking food rather than eating processed or fast foods</li> <li>• Remembering proper fluid intake and hydration</li> <li>• Having a low-fat diet</li> <li>• Using a food diary to identify food triggers- common triggers include red wine and alcohol, chocolate, caffeine in products such as coffee, tea, cola, etc.</li> </ul>
<p><b>Regular and moderate exercise</b> - especially aerobic exercises such as cycling and walking, after careful warm-up. Avoid exercise during their headache attacks</p>
<p><b>Stress management</b> - learning to cope with stressors, problem-solving, social support, changes in living situations and lifestyle, exercise, and avoiding certain situations that cause severe stress and anxiety</p>
<p><b>Weight reduction to restore an ideal body weight</b> might be a useful intervention, to control migraine attacks, especially in obese patients</p>
<p><b>Patient education is an important part of the management of hormonal migraine attacks</b></p>

## STEP 3: RECOMMEND TREATMENT

→ TABLE 9

MEDICATIONS FOR MANAGEMENT OF ACUTE MIGRAINE <sup>1,2</sup>			
Drug Class	Drug	Dosage and Route	Contraindications
<b>First line medications</b>			
<b>Non-steroidal anti-inflammatory drugs (NSAIDs)</b>	Aspirin	900–1000 mg oral	Gastrointestinal bleeding, heart failure
	Ibuprofen	400-600 mg oral	
	Diclofenac	50 mg oral (soluble)	
<b>Other simple analgesics (If NSAIDs are contraindicated)</b>	Paracetamol (Good safety profile at therapeutic levels.)	1000 mg oral	Hepatic disease, renal failure
<b>Combination therapy</b>	Paracetamol + Aspirin + Caffeine <i>(Preferred in patients with contraindications to vasoconstrictors like Triptans)</i>	Acetylsalicylic acid (250 or 265 mg) + paracetamol (200 or 265 mg) + caffeine (50 or 65 mg) oral (2 tablets of FDC)	Contraindications to individual drugs.
<b>Antiemetics (when necessary)</b>	Domperidone	10 mg oral or suppository	Gastrointestinal bleeding, epilepsy, renal failure, cardiac arrhythmia
	Metoclopramide	10 mg oral	Parkinson disease, epilepsy, mechanical ileus
<b>Second-line medications</b>			
<b>Triptans</b>	Sumatriptan	50 or 100 mg oral or 6 mg subcutaneous or 10 or 20 mg intranasal	Cardiovascular or cerebrovascular disease, uncontrolled hypertension, hemiplegic migraine, migraine with brainstem aura  (Caution: Patients who use too frequently may develop medication overuse headache)
	Zolmitriptan	2.5 or 5 mg oral or 5 mg intranasal	
	Almotriptan	12.5 mg oral	
	Eletriptan	20, 40 or 80 mg oral	
	Frovatriptan	2.5 mg oral	
	Naratriptan	2.5 mg oral	
	Rizatriptan	10 mg oral tablet (5 mg if treated with propranolol) or 10 mg mouth- dispersible wafers	

TABLE 9 CONT.

## STEP 3: RECOMMEND TREATMENT

### → TABLE 9 CONT.

Third line medications/newer therapies			
<b>Gepants</b>	Ubrogepant	50, 100 mg oral	Co- administration with strong CYP3A4 Inhibitors
	Rimegepant	75 mg oral	Hypersensitivity, hepatic impairment
<b>Ditans</b>	Lasmiditan	50, 100 or 200 mg oral	Pregnancy, concomitant use with drugs that are P- glycoprotein substrates

#### Summary of pharmacological recommendations for management of acute attacks of migraine:<sup>2</sup>

- Offer acute medication to everyone who experiences migraine attacks.
- Advise use of acute medications early in the headache phase of the attack, as effectiveness depends on timely use with the correct dose.
- Advise patients that frequent, repeated use of acute medication risks development of medication-overuse headache.
- Use NSAIDs (acetylsalicylic acid, ibuprofen or diclofenac potassium) as first- line medication.
- Use Paracetamol when NSAIDs are contraindicated.
- Use Paracetamol as first- line medication for acute treatment of migraine in pregnancy.
- Use triptans as second- line medication.
- Consider combining triptans with fast- acting NSAIDs to avert recurrent relapse.
- Consider ditans and gepants as third- line medications.
- Use prokinetic antiemetics (domperidone or metoclopramide) as adjunct oral medications for nausea and/or vomiting.
- Avoid oral ergot alkaloids, opioids and barbiturates.

## REFERENCES

1. Mayans L, Walling A. Acute Migraine Headache: Treatment Strategies. *Am Fam Physician*. 2018 Feb 15;97(4):243-251.
2. Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. *Nat Rev Neurol*. 2021 Aug;17(8):501-514.
3. Moore N, Pollack C, Butkerait P. Adverse drug reactions and drug-drug interactions with over-the-counter NSAIDs. *Ther Clin Risk Manag*. 2015 Jul 15; 11:1061-75.
4. Vostinaru O. Adverse Effects and Drug Interactions of the Non-Steroidal Anti-Inflammatory Drugs [Internet]. *Nonsteroidal Anti-Inflammatory Drugs*. InTech; 2017. Available from: <http://dx.doi.org/10.5772/intechopen.68198>. Accessed December 2023.
5. Agrawal S, Khazaeni B. Acetaminophen Toxicity. [Updated 2023 Jun 9]. In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK441917/>.
6. John Alchin, Arti Dhar, Kamran Siddiqui & Paul J. Christo (2022) Why paracetamol (acetaminophen) is a suitable first choice for treating mild to moderate acute pain in adults with liver, kidney or cardiovascular disease, gastrointestinal disorders, asthma, or who are older, *Current Medical Research and Opinion*, 38:5, 811-825, DOI: 10.1080/03007995.2022.2049551
7. Meunier L, Larrey D. Recent Advances in Hepatotoxicity of Non-Steroidal Anti-Inflammatory Drugs. *Ann Hepatol*. 2018 Mar 1;17(2):187-191.
8. McEvoy L, Carr DF, Pirmohamed M. Pharmacogenomics of NSAID-Induced Upper Gastrointestinal Toxicity. *Front Pharmacol*. 2021 Jun 21; 12:684162.
9. Ghlichloo I, Gerriets V. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) [Updated 2023 May 1]. In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK547742/>. Accessed December 2023.
10. Haghdoost F, Togha M. Migraine management: Non-pharmacological points for patients and health care professionals. *Open Med (Wars)*. 2022 Nov 23;17(1):1869-1882.
11. Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. *Headache*. 2021 Jul;61(7):1021-1039. doi: 10.1111/head.14153
12. Diener H-C, Holle-Lee D, Nägel S, et al. Treatment of Migraine Attacks and Prevention of Migraine: Guidelines by the German Migraine and Headache Society and the German Society of Neurology. *Clinical and Translational Neuroscience*. 2019; 3(1):3.
13. The International Classification of Headache Disorders 3rd edition. Available at <https://ichd-3.org/1-migraine/>. Accessed on 12th January 2024.
14. Migraine Drug Interactions FAQs- Reviewed on June 17, 2021. Available at <https://americanmigrainefoundation.org/resource-library/migraine-drug-interactions-faq/>. Accessed on 12th January 2024.